ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2020

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.

Huiping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.